SGMO vs. RIGL, VSTM, EBS, VNDA, IRWD, XOMA, CDXS, ACHV, LXRX, and RGLS
Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Emergent BioSolutions (EBS), Vanda Pharmaceuticals (VNDA), Ironwood Pharmaceuticals (IRWD), XOMA (XOMA), Codexis (CDXS), Achieve Life Sciences (ACHV), Lexicon Pharmaceuticals (LXRX), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry.
Sangamo Therapeutics vs.
Sangamo Therapeutics (NASDAQ:SGMO) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.
Sangamo Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500.
Rigel Pharmaceuticals has a net margin of 2.46% compared to Sangamo Therapeutics' net margin of -257.87%. Rigel Pharmaceuticals' return on equity of -14.80% beat Sangamo Therapeutics' return on equity.
Rigel Pharmaceuticals received 12 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 68.98% of users gave Rigel Pharmaceuticals an outperform vote while only 62.67% of users gave Sangamo Therapeutics an outperform vote.
Sangamo Therapeutics currently has a consensus price target of $5.17, suggesting a potential upside of 515.67%. Rigel Pharmaceuticals has a consensus price target of $36.80, suggesting a potential upside of 94.61%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Sangamo Therapeutics is more favorable than Rigel Pharmaceuticals.
Rigel Pharmaceuticals has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Sangamo Therapeutics had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 4 mentions for Sangamo Therapeutics and 3 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 1.16 beat Sangamo Therapeutics' score of 0.02 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.
56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 2.8% of Sangamo Therapeutics shares are owned by company insiders. Comparatively, 9.0% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Rigel Pharmaceuticals beats Sangamo Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Sangamo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sangamo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SGMO) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy SGMO Stock Free SGMO Stock Alerts